2-amino-(2R)-cyclopentyl-ethanol | 223473-36-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-amino-(2R)-cyclopentyl-ethanol
• 英文别名: (2R)-2-Amino-2-cyclopentylethan-1-ol；(2R)-2-amino-2-cyclopentylethanol
• CAS: 223473-36-7
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: REQSKJYQZWAJFK-ZETCQYMHSA-N

物化性质

• 熔点：
  61-62 °C
• 沸点：
  255.9±13.0 °C(Predicted)
• 密度：
  1.029±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-amino-(2R)-cyclopentyl-ethanol 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 19.33h， 生成
  参考文献：
  名称：

  New Expedient Route to Both Enantiomers of Nonproteinogenic α-Amino Acid Derivatives from the Unsaturated 2-Aza-Bicyclo Moiety

  摘要：

  The influence of the reaction conditions on the catalytic hydrogenation of 2-aza-bicyclo hept-5-ene and oct-5-ene derivatives has been investigated. We found it possible to fully control the extent of allylic vs benzylic C-N hydrogenolysis by simple variations of H-2 pressure and acidity of the reaction medium. The use of the reaction pathways was demonstrated by the selective preparation of four categories of optically active alpha-amino acid derivatives. The strategy was also extended to the synthesis of enantiopure alpha-amino ketones.

  DOI：

  10.1021/jo981838w
• 作为产物：
  描述：

  (1R,3R,4S)-2-<(1S)-phenylethyl>-2-aza-bicyclo<2.2.1>hept-5-ene-3-carboxylic acid ethyl ester 在 palladium on activated charcoal lithium aluminium tetrahydride 、 氢气 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 6.17h， 生成 2-amino-(2R)-cyclopentyl-ethanol
  参考文献：
  名称：

  New Expedient Route to Both Enantiomers of Nonproteinogenic α-Amino Acid Derivatives from the Unsaturated 2-Aza-Bicyclo Moiety

  摘要：

  The influence of the reaction conditions on the catalytic hydrogenation of 2-aza-bicyclo hept-5-ene and oct-5-ene derivatives has been investigated. We found it possible to fully control the extent of allylic vs benzylic C-N hydrogenolysis by simple variations of H-2 pressure and acidity of the reaction medium. The use of the reaction pathways was demonstrated by the selective preparation of four categories of optically active alpha-amino acid derivatives. The strategy was also extended to the synthesis of enantiopure alpha-amino ketones.

  DOI：

  10.1021/jo981838w

文献信息

• Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: Part 1
  作者：Julius J. Matasi、Stephanie Brumfield、Deen Tulshian、Michael Czarnecki、William Greenlee、Charles G. Garlisi、Hongchen Qiu、Kristine Devito、Shu-Cheng Chen、Youngliang Sun、Rosalia Bertorelli、William Geiss、Van-Duc Le、Gregory S. Martin、Samuel A. Vellekoop、James Haber、Melissa L. Allard

  DOI：10.1016/j.bmcl.2011.04.034

  日期：2011.6

  Structure–activity relationship (SAR) efforts around our initial lead compound 1 led to the identification of potent P2X7 receptor antagonists with improved pharmacokinetic profiles. These compounds were potent and selective at the P2X7 receptor in both human and rodent. Compound (entry 31) exhibited oral efficacy in the rat MIA and CCI pain models.

  围绕我们最初的先导化合物1的结构-活性关系（SAR）的努力导致鉴定出具有改善的药代动力学特征的有效P2X 7受体拮抗剂。这些化合物在人和啮齿动物中均对P2X 7受体有效且具有选择性。化合物（第31项）在大鼠MIA和CCI疼痛模型中表现出口服功效。
• DIPEPTIDYL PEPTIDASE-IV INHIBITORS
  申请人：Kroth Heiko

  公开号：US20100009961A1

  公开（公告）日：2010-01-14

  The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.
• Dipeptidyl Peptidase-IV Inhibitors
  申请人：KROTH Heiko

  公开号：US20110112051A1

  公开（公告）日：2011-05-12

  The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.
• US7553861B2
  申请人：——

  公开号：US7553861B2

  公开（公告）日：2009-06-30
• US8076330B2
  申请人：——

  公开号：US8076330B2

  公开（公告）日：2011-12-13